Your practitioner will review your symptoms, health history, and any existing test results to determine the most appropriate treatment protocol
AOD-9604 vs Other Research Peptides AOD-9604 sits in a different mechanistic category than most of the compounds its commonly compared against its the only one on this list that acts directly on fat tissue without touching appetite signaling or the growth hormone axis

hospitalization required Maintenance of Remission: Immunomodulators (azathioprine, 6-MP, methotrexate) for steroid-dependent or frequently-relapsing disease Biologic monotherapy or combination therapy (biologic + immunomodulator) for moderate-to-severe disease Step-up or top-down approach based on disease severity, patient risk factors, and prior therapy Biologic Therapy Targets: TNF-: Infliximab (IV), adalimumab (SC), certolizumab pegol (SC) IL-12/23: Ustekinumab (IV induction, SC maintenance) Integrin: Vedolizumab (IV) IL-23: Risankizumab (IV induction, SC maintenance) JAK inhibition: Upadacitinib (oral) Surgical Management Surgery is indicated in approximately 7080% of patients with Crohns disease over their lifetime, per StatPearls
This highlights the importance of a sustained approach to weight management, ensuring that patients continue to receive the benefits of the medication over the long term